Rivka Dikstein

Title: Rivka Dikstein: Innovator in Transcription Factor Research

Introduction

Rivka Dikstein is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of molecular biology, particularly in the area of transcription factors. Her work has implications for both therapeutic and diagnostic applications in the biopharmaceutical industry.

Latest Patents

Rivka Dikstein holds a patent for a cell-type specific transcription factor. The invention provides methods and compositions relating to human tata-binding protein associated factor 105 (hTAF.sub.II 105) and related nucleic acids. The proteins may be produced recombinantly from transformed host cells using the disclosed hTAF.sub.II 105 encoding nucleic acids or purified from human cells. The invention also includes isolated hTAF.sub.II 105 hybridization probes and primers capable of specifically hybridizing with the disclosed hTAF.sub.II 105 gene, as well as hTAF.sub.II 105-specific binding agents such as specific antibodies. These innovations are crucial for diagnosis, therapy, and applications in the biopharmaceutical industry.

Career Highlights

Rivka Dikstein has had a distinguished career, contributing to various research projects and advancing the understanding of transcription factors. Her work has been recognized in academic circles, and she continues to be an influential figure in her field.

Collaborations

Rivka has collaborated with notable scientists, including Robert Tjian, enhancing the impact of her research through shared expertise and resources.

Conclusion

Rivka Dikstein's innovative work in transcription factor research exemplifies the importance of scientific inquiry in advancing medical and biopharmaceutical applications. Her contributions continue to shape the landscape of molecular biology and therapeutic development.